CULVER CITY, Calif., Dec. 14, 2001 (PRIMEZONE) -- Careside, Inc. (AMEX:CSA), a provider of point-of-care blood analysis instrumentation and records management, announced today that its registration statement on Form S-3 that registers the shares of Common Stock issued in connection with the Company's Series C Preferred Stock financing, which was completed earlier in 2001, was declared effective on December 7, 2001 by the Securities and Exchange Commission. The total number of shares of Common Stock included in the Registration Statement was 12,894,155.
Copies of the final prospectus may be obtained from Careside's office at 6100 Bristol Parkway, Culver City, CA 90230. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the Company's capital stock in any state in which such offer, solicitation or sale would be unlawful.
About Careside, Inc.
Careside, Inc. markets a proprietary blood testing system including its CARESIDE Analyzer, a companion hematology system called the H-2000 Hematology Analyzer, and its CARESIDE Connect record management system linking patient test results into a single report. The CARESIDE Analyzer provides a cost-effective and efficient means of measuring blood chemistry, electrochemistry, and coagulation function near the patient by producing accurate test results within 15 minutes. Careside, Inc. is one of the world's leading developers of advanced point-of-care blood testing technology. For more information on the Company, access www.careside.com.
Safe Harbor: Statements in this press release regarding Careside, Inc. which are not historical facts are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include risks associated with marketing and performance of Careside products. Careside undertakes no obligation to update forward-looking statements. Please see the risk factors listed from time to time in Careside's prospectus and reports on file with the SEC.